| Literature DB >> 29805558 |
Junxi Dai1, Yanbin Ma1, Shenghua Chu1, Nanyang Le1, Jun Cao1, Yang Wang2.
Abstract
Meningioma is the most frequently occurring type of brain tumor. The present study aimed to conduct a comprehensive bioinformatics analysis of key genes and relevant pathways involved in meningioma, and acquire further insight into the underlying molecular mechanisms. Initially, differentially expressed genes (DEGs) in 47 meningioma samples as compared with 4 normal meninges were identified. Subsequently, these DEGs were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. In addition, a protein-protein interaction (PPI) network of the identified DEGs was constructed using the Search Tool for the Retrieval of Interacting Genes and visualized using Cytoscape. In total, 1,683 DEGs were identified, including 66 upregulated and 1,617 downregulated genes. The GO analysis results revealed that the DEGs were significantly associated with the 'protein binding', 'cytoplasm', 'extracellular matrix (ECM) organization' and 'cell adhesion' terms. The KEGG analysis results demonstrated the significant pathways included 'AGE-RAGE signaling pathway in diabetic complications', 'PI3K-Akt signaling pathway', 'ECM-receptor interaction' and 'cell adhesion molecules'. The top five hub genes obtained from the PPI network were JUN, PIK3R1, FOS, AGT and MYC, and the most enriched KEGG pathways associated with the four obtained modules were 'chemokine signaling pathway', 'cytokine-cytokine receptor interaction', 'allograft rejection', and 'complement and coagulation cascades'. In conclusion, bioinformatics analysis identified a number of potential biomarkers and relevant pathways that may represent key mechanisms involved in the development and progression of meningioma. However, these findings require verification in future experimental studies.Entities:
Keywords: bioinformatics; biomarker; meningioma; protein-protein interaction; signaling pathway
Year: 2018 PMID: 29805558 PMCID: PMC5950024 DOI: 10.3892/ol.2018.8376
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1.Heat map of differentially expressed genes associated with meningioma. The data are presented in a matrix format, in which rows represent individual genes and columns represent each sample. The red and green colors indicate upregulated and downregulated genes, respectively.
GO analysis of differentially expressed genes associated with meningioma.
| Category | Term | Count | P-value |
|---|---|---|---|
| GOTERM_MF_DIRECT | Protein binding | 931 | 5.26×10−15 |
| GOTERM_CC_DIRECT | Cytoplasm | 587 | 1.36×10–13 |
| GOTERM_BP_DIRECT | Extracellular matrix organization | 53 | 1.22×10−12 |
| GOTERM_CC_DIRECT | Cytosol | 397 | 2.33×10–12 |
| GOTERM_BP_DIRECT | Cell adhesion | 91 | 2.85×10−12 |
| GOTERM_CC_DIRECT | Extracellular exosome | 344 | 8.41×10–12 |
| GOTERM_CC_DIRECT | Extracellular matrix | 61 | 5.24×10−10 |
| GOTERM_CC_DIRECT | Focal adhesion | 73 | 9.24×10–10 |
| GOTERM_CC_DIRECT | Z disc | 34 | 1.06×10−9 |
| GOTERM_BP_DIRECT | Angiogenesis | 51 | 2.10×10-9 |
| GOTERM_CC_DIRECT | Extracellular space | 181 | 2.87×10−9 |
| GOTERM_BP_DIRECT | Signal transduction | 166 | 5.42×10-9 |
| GOTERM_BP_DIRECT | Positive regulation of transcription from RNA polymerase II promoter | 140 | 1.15×10−7 |
| GOTERM_CC_DIRECT | Extracellular region | 201 | 1.16×10-7 |
| GOTERM_MF_DIRECT | Transcription factor binding | 54 | 2.02×10−7 |
| GOTERM_CC_DIRECT | Stress fiber | 19 | 3.71×10-7 |
| GOTERM_BP_DIRECT | Positive regulation of angiogenesis | 30 | 3.72×10−7 |
| GOTERM_MF_DIRECT | Identical protein binding | 109 | 3.97×10-7 |
| GOTERM_CC_DIRECT | Integral component of plasma membrane | 178 | 4.34×10−7 |
| GOTERM_CC_DIRECT | Cell surface | 83 | 6.11×10-7 |
| GOTERM_BP_DIRECT | Type I interferon signaling pathway | 21 | 6.20×10−7 |
| GOTERM_BP_DIRECT | Negative regulation of cell proliferation | 68 | 6.72×10-7 |
| GOTERM_BP_DIRECT | Immune response | 71 | 7.37×10−7 |
| GOTERM_BP_DIRECT | Response to hypoxia | 38 | 7.54×10-7 |
| GOTERM_CC_DIRECT | Myelin sheath | 34 | 7.94×10−7 |
| GOTERM_CC_DIRECT | Membrane raft | 41 | 1.24×10-6 |
| GOTERM_CC_DIRECT | Neuron projection | 45 | 1.34×10−6 |
| GOTERM_CC_DIRECT | Actin filament | 20 | 1.73×10-6 |
| GOTERM_BP_DIRECT | Positive regulation of apoptotic process | 54 | 2.63×10−6 |
| GOTERM_CC_DIRECT | Proteinaceous extracellular matrix | 48 | 3.10×10-6 |
GO, Gene ontology; MF, molecular function; CC, cellular component; BP, biological process.
Enriched Kyoto Encyclopedia of Genes and Genomes pathways of differentially expressed genes associated with meningioma.
| Pathway ID | Description | Gene count | P-value |
|---|---|---|---|
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 32 | 7.86×10−9 |
| hsa04151 | PI3K-Akt signaling pathway | 70 | 3.98×10-8 |
| hsa04668 | TNF signaling pathway | 32 | 7.73×10−8 |
| hsa04512 | ECM-receptor interaction | 26 | 1.98×10-7 |
| hsa04510 | Focal adhesion | 46 | 3.84×10−7 |
| hsa05410 | Hypertrophic cardiomyopathy | 23 | 1.28×10-5 |
| hsa04066 | HIF-1 signaling pathway | 26 | 2.21×10−5 |
| hsa04210 | Apoptosis | 32 | 2.36×10-5 |
| hsa05146 | Amoebiasis | 25 | 2.62×10−5 |
| hsa05414 | Dilated cardiomyopathy | 23 | 5.30×10-5 |
| hsa05200 | Pathways in cancer | 67 | 9.01×10−5 |
| hsa05144 | Malaria | 15 | 1.21×10-4 |
| hsa05222 | Small cell lung cancer | 21 | 2.22×10−4 |
| hsa05134 | Legionellosis | 15 | 4.93×10-4 |
| hsa05031 | Amphetamine addiction | 17 | 6.46×10−4 |
| hsa04657 | IL-17 signaling pathway | 21 | 6.90×10-4 |
| hsa05161 | Hepatitis B | 29 | 7.24×10−4 |
| hsa04978 | Mineral absorption | 14 | 8.68×10-4 |
| hsa04068 | FoxO signaling pathway | 27 | 8.68×10−4 |
| hsa04010 | MAPK signaling pathway | 44 | 9.13×10-4 |
| hsa04064 | NF-κB signaling pathway | 21 | 9.27×10−4 |
| hsa04060 | Cytokine-cytokine receptor interaction | 46 | 9.30×10-4 |
| hsa05416 | Viral myocarditis | 15 | 1.10×10−3 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 17 | 1.29×10-3 |
| hsa05202 | Transcriptional misregulation in cancer | 33 | 1.39×10−3 |
| hsa04514 | Cell adhesion molecules | 28 | 1.40×10-3 |
| hsa05166 | HTLV–I infection | 43 | 2.10×10−3 |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 28 | 2.14×10-3 |
| hsa04022 | cGMP-PKG signaling pathway | 30 | 3.39×10−3 |
| hsa04145 | Phagosome | 28 | 3.51×10-3 |
| hsa04610 | Complement and coagulation cascades | 17 | 3.71×10−3 |
| hsa04621 | NOD-like receptor signaling pathway | 30 | 4.06×10-3 |
| hsa05162 | Measles | 25 | 4.86×10−3 |
| hsa04921 | Oxytocin signaling pathway | 28 | 5.09×10-3 |
Hub genes and their corresponding degree.
| Gene symbol | Degree |
|---|---|
| JUN | 79 |
| PIK3R1 | 56 |
| FOS | 53 |
| AGT | 53 |
| MYC | 50 |
| STAT3 | 47 |
| LPAR1 | 47 |
| IL8 | 44 |
| HSP90AA1 | 41 |
| CXCL12 | 41 |
| NFKB1 | 41 |
| RPS27A | 40 |
| GNAI1 | 39 |
| PPBP | 37 |
| CXCR4 | 35 |
| HIF1A | 33 |
| NPY | 32 |
| S1PR1 | 32 |
| CCL5 | 31 |
| SST | 30 |
| IL6 | 30 |
| EDN1 | 30 |
| EGR1 | 28 |
| STAT1 | 28 |
| IRF1 | 28 |
| CCR7 | 28 |
| CXCL2 | 28 |
| SSTR2 | 27 |
| CCL19 | 27 |
| RGS1 | 27 |
| RGS4 | 27 |
| CXCL9 | 27 |
| CXCL1 | 27 |
| ADRA2A | 27 |
| HTR1B | 27 |
| HTR1D | 27 |
| CXCL3 | 27 |
| C5AR1 | 27 |
| MTNR1B | 27 |
| APLNR | 27 |
| P2RY14 | 27 |
| HCAR3 | 27 |
| ICAM1 | 25 |
| CDKN1A | 24 |
| CCND1 | 23 |
| PTEN | 23 |
| NOS3 | 23 |
| ACTN1 | 23 |
| IRF7 | 23 |
| KALRN | 23 |
| IRF9 | 22 |
| HLA-A | 22 |
| YWHAE | 22 |
| SIRT1 | 21 |
| CDH1 | 21 |
| GNAQ | 21 |
| ISG15 | 20 |
Figure 2.Top 4 modules with the higher connectivity degrees identified in the protein-protein interaction network analysis. (A) Module 1, (B) module 2, (C) module 3 and (D) module 4 are shown.
Enriched Kyoto Encyclopedia of Genes and Genomes pathways of four modules.
| Pathway term | P-value | Nodes |
|---|---|---|
| Module 1 | ||
| Chemokine signaling pathway | 1.14×10−10 | CXCL1, CCR7, PPBP, IL8, GNAI1, CXCR4, CXCL3, CXCL2, CXCL9, CCL19, CCL5, CXCL12 |
| Cytokine-cytokine receptor interaction | 7.02×10-8 | CXCL1, CCR7, PPBP, IL8, CXCR4, CXCL3, CXCL2, CXCL9, CCL19, CCL5, CXCL12 |
| Neuroactive ligand-receptor interaction | 7.93×10−7 | APLNR, HTR1B, SSTR2, C5AR1, S1PR1, P2RY14, ADRA2A, MTNR1B, LPAR1, HTR1D |
| Module 2 | ||
| Allograft rejection | 0.0418 | HLA-A, HLA-C |
| Graft-versus-host disease | 0.0452 | HLA-A, HLA-C |
| Type I diabetes mellitus | 0.0486 | HLA-A, HLA-C |
| Module 3 | ||
| No record | – | – |
| Module 4 | ||
| Complement and coagulation cascades | 0.0012 | VWF, A2M, F13A1, SERPINE1 |
| Calcium signaling pathway | 0.0018 | AGTR1, EDNRB, GNAQ, PTGFR, HTR2A |
| Renal cell carcinoma | 0.0198 | VEGFC, TGFB3, PIK3R1 |